CR845—an oral, peripherally selective kappa opioid agonist—is currently in Phase 2 trials for the treatment of pruritus, and acute and chronic pain.1 Eighty patients with hip osteoarthritis (OA) or knee OA were randomized to receive treatment with 0.25 mg, 0.5 mg, 1.0 mg or 5.0 mg CR845 twice daily for two weeks. Safety assessment, pharmacokinetics…
Search results for: Secukinumab
3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA
Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…
New SLE Drug May Allow Patients to Reduce Steroid Use
In a recent study, the use of anifrolumab in SLE patients was shown to be safe and effective, enabling some patients to decrease their oral steroids. Also, secukinumab has been approved in Europe to treat ankylosing spondylitis and psoriatic arthritis…
Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis
NEW YORK (Reuters Health)—Obese patients with psoriasis or psoriatic arthritis are apt to experience significant symptomatic relief following bariatric surgery, according to a new chart review. Specifically, the study found that more than half of the patients with psoriasis or psoriatic arthritis reported improvements in their disease following surgery. Dr. Soumya Reddy, assistant professor of…
XenoPort’s Psoriasis Drug Found Effective in Phase 2 Trial
(Reuters)—Drug developer XenoPort Inc. said on Tuesday its experimental drug was effective in treating psoriasis, sending its shares up 19% in premarket trading. The oral drug met the main goal in a phase 2 trial of patients with moderate-to-severe chronic plaque-type psoriasis, the company said. XenoPort said it expected to start late-stage trials next year…
Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments
PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…
Data Collection Drives Evaluation of Psoriasis Treatments
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
Drug Interactions for Trimethoprim/ Sulfamethoxazole Come to Light
Plus, updates on buprenorphine, diclofenac sodium, secukinumab and other rheumatology drug news, safety information
2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis
Clinical manifestations, approaches to diagnosis, treatment
The ACR/ARHP Annual Meeting: Rheumatoid Arthritis Raises Mortality Risk in Women
Data from Nurses’ Health Study, other clinical trials point to higher risk of respiratory, cardiovascular disease death in women with RA
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »